Linagliptin
Established medicineAlso known as Glyxambi, Jentadueto, Tradjenta, Trijardy+2 more
Glyxambi, Jentadueto, Tradjenta, Trijardy, Linagliptina, (R)-8-(3-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione.
Recent clinical, regulatory, research and industry developments relating to this drug.
Label change: EMPAGLIFLOZIN, LINAGLIPTIN, METFORMIN HYDROCHLORIDE (NDA212614)
Label change: LINAGLIPTIN AND METFORMIN HYDROCHLORIDE (NDA201281)
Label change: LINAGLIPTIN AND METFORMIN HYDROCHLORIDE (NDA208026)
Label change: EMPAGLIFLOZIN, LINAGLIPTIN, METFORMIN HYDROCHLORIDE (NDA212614)
Effect of Linagliptin on Vascular Function: A Randomized, Placebo-controlled Study.
Evidence confidence
How strongly the incorporated evidence supports specific clinical claims about this treatment. A confidence figure is a current summary of evidence strength, not a permanent verdict.
High point estimate, but substantial uncertainty remains.
Confidence has a moderate point estimate but a wide uncertainty band — the evidence is still sponsor-concentrated.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Trajenta is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults: as monotherapy in patients inadequately controlled by diet and exercise… Show full indicationShow less
Trajenta is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults: as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment. as combination therapy in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes1
Journals, researchers & institutions
- The Journal of clinical endocrinology and metabolism1
- Baltzis D1
- Dushay JR1
- Greenman RL1
- Loader J1
- Roustit M1
- Veves A1
- Wu J1
- Microcirculatory Laboratory and Rongxiang Xu1
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.